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Purpose: Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase 
(GNE) myopathy is an autosomal recessive neuromuscular disorder characterized 
by early adult-onset weakness of the distal muscles of the lower limbs. The clinical 
spectrum of GNE myopathy varies, and it is not clear how the same GNE gene mu-
tations can result in different phenotypes. Here, we present clinical, pathological 
and genetic characteristics of twenty-one Korean patients with GNE myopathy. 
Materials and Methods: Twenty-one GNE myopathy patients were included in 
this study, conducted from 2004 to 2011. Based on medical records, patients’ gen-
der, onset age, family history, clinical history, serum creatine kinase (CK) level, 
neurologic examination, findings of muscle biopsy, muscle imaging findings and 
electrophysiologic features were extensively reviewed. Mutation of the GNE gene 
(9p13.3) was confirmed by DNA direct sequencing analysis in all patients. Results: 
The mean onset age was 23.8±8.8 years (mean±SD). Patient serum CK levels were 
slightly to moderately elevated, ranging from 41 to 2610 IU. Among the patients, 
twelve patients were female and nine patients were male. Except for eight patients, 
all of the patients presented initially with only distal muscle weakness in the lower 
extremities. The most common mutation was V572L, followed by C13S. Conclu-
sion: The clinical manifestations of our patients with GNE mutations varied. 
Among twenty-one patients, thirteen patients showed the typical GNE myopathy 
phenotype. There was no relationship between clinical features and site of mutation. 
Therefore, we suggest that neither homozygous nor compound heterozygous mod-
els are correlated with disease phenotype or disease severity.
Key Words:   GNE, phenotype, genotype
INTRODUCTION
Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE) 
myopathy, otherwise known as Nonaka myopathy1 or hereditary inclusion body 
myopathy2,3 is an autosomal recessive neuromuscular disorder characterized by 
early adult-onset weakness of the distal muscles of the lower limbs. The tibialis an-
terior is typically affected, while the quadriceps group is typically spared.3 Patients 
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pital. Such data included the patients’ gender, age at symp-
tom onset, family history, clinical history, serum CK level, 
neurologic examination, findings of muscle biopsy, muscle 
imaging findings and electrophysiologic features. 
Genetic analysis 
After informed consent was obtained, blood samples were 
obtained from suspicious patients and DNA study was per-
formed. Mutation of the GNE gene (9p13.3) was confirmed 
by DNA direct sequencing analysis in all patients. Genomic 
DNA was extracted from peripheral blood leukocytes using 
a genomic DNA extract kit (Easy-DNA kit, Invitrogen). 
All 11 coding exons (exon 2-12) of the GNE gene were 
amplified by performing PCR using forward and reverse 
primers. Mutations were identified with reference to the 
Human Gene Mutation Database.
 
RESULTS
 
Clinical and pathological data, as well as data on GNE mu-
tations, of the Korean patients with GNE myopathy are 
summarized in Table 1. The mean onset age was 23.8±8.8 
years (mean±SD). Among these patients, twelve patients 
were female and nine patients were male. The mean onset 
age in females was 23.6±9.9 years (mean±SD), and the 
mean onset age in males was 24.1±7.6 years (mean±SD). 
Patient serum creatine kinase levels were slightly to moder-
ately elevated, ranging from 41 to 2610 IU. Four patients 
presented with a family history of GNE gene mutation. Ex-
cept for eight patients, all of the patients presented initially 
with only distal muscle weakness in the lower extremities. 
However, these patients showed different sites of progress-
ing weakness. Two patients initially showed weakness in 
the upper extremities, while the others initially showed proxi-
mal or both proximal and distal weakness in the lower ex-
tremities. Electromyogram studies showed a myopathic or 
mixed pattern in all patients. Eleven of twenty-one patients 
underwent muscle biopsy. On muscle biopsy, five patients 
exhibited rimmed vacuoles of myofibers. Five patients un-
derwent muscle imaging. Except for one patient, the tibialis 
anterior was the most severely affected muscle, while the 
quadriceps were relatively spared. Direct nucleotide se-
quencing disclosed fifteen compound heterozygous GNE 
mutations and six homozygous GNE mutations. In addi-
tion, one patient was found to have only one heterozygous 
mutation. Because single heterozygous mutations was not 
with GNE myopathy exhibit mildly elevated serum creatine 
kinase (CK) levels.
This disease is caused by mutations in the UDP-N-acetyl-
glucosamine 2-epimerase/N-acetylmannosamine kinase 
(GNE) gene that regulates the synthesis of sialic acid.4,5 The 
GNE gene encodes a bifunctional protein with two enzymat-
ic activities: UDP-GlcNAc2-epimerase (GNE) and ManNAc 
kinase.6 More than 70 GNE mutations have been described 
to be associated with GNE myopathy in patients of different 
ethnic origin. Two mutations are frequently observed in two 
specific ethnic groups, M712T in Middle Eastern Jews and 
V572L in Japanese patients, suggesting a founder effect.2,7,8  
Although the molecular mechanism by which the muta-
tions in the GNE gene cause the muscle degeneration seen 
in GNE myopathy remains unclear, it has been proposed 
that the mutations may lead to defective sialylation of mus-
cle tissue.9,10 One characteristic histopathological feature is 
the presence of numerous rimmed vacuoles, which are im-
munoreactive to various proteins.11 Despite these findings, 
the pathophysiological mechanisms underlying rimmed 
vacuole formation remain to be elucidated. 
The clinical spectrum of GNE myopathy varies, as the 
prominent initial symptoms and advanced symptoms are 
different for each patient.7,12 However, it is not clear how the 
same GNE gene mutations can result in different pheno-
types. Herein, we report clinical characteristics and molecu-
lar genetic analysis of Korean patients with GNE myopathy.
MATERIALS AND METHODS
　　　
Subjects
Twenty-one GNE myopathy patients were included in this 
study, conducted from 2004 to 2011. All patients exhibited 
the following suspicious features of GNE myopathy: 1) au-
tosomal recessive or sporadic; 2) early adult onset; 3) the 
initial symptom of gait disturbance due to weakness, typi-
cally in the anterior compartment of the distal leg; and 4) 
myopathic changes on electromyography. All patients were 
evaluated neurologically and were referred for genetic test-
ing with informed consent. Of those, only patients with con-
firmed mutation of the GNE gene by DNA analysis were 
enrolled in this study. 
Clinical data collection
Clinical data for each patient were obtained by reviewing all 
records available in the electronic medical records at the hos-
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compound heterozygous mutations in different domains of 
the protein, but demonstrated different phenotypes.17 Even 
with the same homozygous mutation, there appears to be 
heterogeneities in the severity of the clinical presentations.7,14 
Also, our data showed that there was no relationship be-
tween clinical features and mutation site. Therefore, we sug-
gest that neither homozygous nor compound heterozygous 
models are correlated with disease phenotype or disease se-
verity. Recently, V572L mutation was suggested to be asso-
ciated with disease severity.18 However, for more detailed 
information on the genotype-phenotype correlation and the 
effect of the mutation site, further clinical and genetic anal-
yses are needed, along with review of the natural course of 
this disease.
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